HIPGEN

HIPGEN PARTNERSHIP

The Network consists of 10 partners from 8 Countries (Germany, Denmark, UK, Ireland, Italy, Switzerland and Israel, US).
The clinical and research centers in the Consortium have a renowned international expertise on hip fracture arthroplasty and cell therapy respectively while Pluristem is a lead company in the cell therapy development. All the Partners have been selected for their excellence in the field.
The HIPGEN consortium includes also the Irish CRO ICON that will manage the multicentre clinical trial, the company Be the Partner that has developed the platform for patient data management and the service provider company INN-ACTA that will support the consortium in the coordination, dissemination and exploitation, allowing the scientists to focus on the science and the business developer on business. Finally, the International Osteoporosis foundation gives an added value of the consortium by filling the communication gap between science and patients.
The high degree of synergy among our participants ensures that the program will be successful and that their combined output will be greater than the sum of its parts. The European dimension of the project is an added value of the proposal, in terms of achieving the necessary critical mass (regarding patient enrollment, clinical infrastructures, availability of samples for analysis), financial support and good visibility.